Please provide your email address to receive an email when new articles are posted on . Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin ...

(HealthDay News) — A hepatitis C virus (HCV) screening program diagnosed chronic HCV infection in 4.2% of baby boomers tested, according to a study published in the August issue of the Journal of ...

As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

WASHINGTON, DC — "We don't get to use the 'eliminate' word all that often with a disease that's taking thousands or tens of thousands — or worldwide, hundreds of thousands — of lives every year, but ...

Please provide your email address to receive an email when new articles are posted on . Intent Solutions announced a partnership with the University of Kentucky in a $15 million federal grant program ...

Atea Pharmaceuticals, Inc. ( (AVIR)) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to its investors. Atea Pharmaceuticals, Inc. is a ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

Dr. James W. Galbraith joined the University of Alabama at Birmingham (UAB) Emergency Medicine faculty in 2008. In 2011, Dr. Galbraith led the implementation of emergency department (ED) non-targeted, ...